HuidaGene Therapeutics is a global clinical-stage biotechnology company specializing in CRISPR-based genomic medicines. Founded in 2018 and headquartered in Shanghai with an additional office in Clinton, New Jersey, HuidaGene focuses on developing precise, one-time gene therapies aimed at treating life-threatening conditions. Their innovative platform leverages advanced CRISPR/Cas13 and Cas12 technologies to target and edit RNA and DNA, respectively, offering potential cures for diseases that currently have limited treatment options.​